Test of cure was not routinely performed, with patients discharged as "initial cures" once they completed a full course of VL treatment and showed clinical improvement, cessation of fever, reduction of spleen size, and return of appetite at the time of discharge as per WHO descriptions of treatment response [ 15].
Patient showed clinical improvement with cessation of fever, improvement in appetite and weight gain.
The patient remained sick with no improvement of his fever or leucocytes count which was below 0.5/μL.
In this review, we highlight advances in the field of C. burnetii proteomics, focusing mainly on the contribution of these technologies to the development and improvement of Q fever diagnostics.
On admission the patient was started on ceftriaxone and clindamycine leading to no clinical improvement except cessation of fever but CRP even rose (129 mg/L).
The patient subsequently improved clinically with resolution of fever and improvement of haemodynamic parameters.
In this prospective, double-blinded, randomized study comparing methylprednisolone (MPDN) to a placebo combined with ceftriaxone plus levofloxacin in severe CAP, MPDN administration was associated with improved oxygenation, faster decrease of fever and radiological improvement.
Improvement in the degree of fever and anorexia were noted as early as 24 hrs after the start of treatment in all animals.
The main outcome will be clinical cure at 14 days, defined as absence of fever, resolution or improvement of cough, improvement of general wellbeing and resolution or reduction of crackles indicating that no other antimicrobial treatment will be necessary.
The variable of the main result will be clinical cure at 14 days, defined as absence of fever, resolution or improvement of cough, improvement of general wellbeing and normal respiratory auscultation or reduction of crackles indicating that no other antimicrobial treatment is necessary.
